Get the Stockscreener App
35.55
1.17%
0.41
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Axogen Inc stock is traded at $35.55, with a volume of 391.88K.
It is up +1.17% in the last 24 hours and down -20.95% over the past month.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
See More
Previous Close:
$35.14
Open:
$35.14
24h Volume:
391.88K
Relative Volume:
0.22
Market Cap:
$2.09B
Revenue:
$238.11M
Net Income/Loss:
$-31.45M
P/E Ratio:
-56.13
EPS:
-0.6334
Net Cash Flow:
$7.66M
1W Performance:
-1.74%
1M Performance:
-20.95%
6M Performance:
+2.27%
1Y Performance:
+120.53%
1-Day Range:
$35.14
$36.42
1-Week Range:
$35.03
$37.40
52-Week Range:
$15.27
$52.91
Axogen Inc Stock (AXGN) Company Profile
Name
Axogen Inc
Sector
Industry
Phone
(386) 462-6817
Address
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
35.55 | 2.09B | 238.11M | -31.45M | 7.66M | -0.6334 |
ABT
Abbott Laboratories
|
104.59 | 180.98B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
95.30 | 121.90B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
291.61 | 111.85B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.80 | 63.48B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.65 | 49.95B | 6.30B | 1.07B | 1.09B | 1.8406 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-12-26 | Initiated | BofA Securities | Buy |
| Oct-07-26 | Initiated | Barclays | Overweight |
| Aug-26-26 | Initiated | Truist | Buy |
| Feb-19-26 | Initiated | Wells Fargo | Overweight |
| Dec-01-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Lake Street | Buy |
| Jul-01-24 | Initiated | Raymond James | Outperform |
| Nov-11-22 | Resumed | Jefferies | Buy |
| May-09-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-11-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| May-07-20 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-02-20 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-12-19 | Initiated | Canaccord Genuity | Buy |
| Mar-02-18 | Reiterated | Lake Street | Buy |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-30-17 | Initiated | Jefferies | Buy |
| Nov-21-17 | Reiterated | Lake Street | Buy |
| Jul-31-17 | Initiated | Leerink Partners | Outperform |
| Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-17 | Initiated | ROTH Capital | Buy |
| Nov-22-16 | Upgrade | Lake Street | Hold → Buy |
| Nov-07-16 | Reiterated | Wedbush | Outperform |
| Nov-03-16 | Downgrade | Lake Street | Buy → Hold |
| Aug-04-16 | Reiterated | Wedbush | Outperform |
| May-14-14 | Initiated | Dawson James | Buy |
| Oct-31-13 | Reiterated | Ladenburg Thalmann | Buy |
View All
Axogen Inc Stock (AXGN) Latest News
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research
Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN) - Zacks Investment Research
A passive stake above 5% in Axogen (AXGN) is held through advisory clients. - Stock Titan
AXGN | Axogen, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Axogen, Inc.Common Stock (Nasdaq:AXGN) Stock Quote - The Chronicle-Journal
Axogen deepens nerve repair portfolio through $200m BioCircuit takeover - Yahoo Finance
Axogen announces pricing of public offering - medicalbuyer.co.in
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com Australia
Axogen Inc (AXGN) Shares Fall 11.5% -- What GF Score of 64 Tells Investors - GuruFocus
AXGN 424B FilingsAxogen Inc SEC 424B - Stock Titan
Axogen To Acquire BioCircuit Technologies For $200 Million To Add Sutureless Nerve Repair Platform - Pulse 2.0
Why Is Axogen Stock Tumbling Today?Axogen (NASDAQ:AXGN) - Benzinga
Axogen to buy BioCircuit Technologies for $200M - medtechdive.com
Axogen Announces $200 Million Acquisition of BioCircuit Technologies Alongside $42.50 Per Share Stock Offering - Kalkine Media
Axogen to acquire Biocircuit for $200M - BioWorld News
2 Medical-Device Stocks Lighting Up the Options Pits - schaeffersresearch.com
Form 8K Axogen Inc For: 10 September By Investing.com - Investing.com South Africa
Axogen stock falls as $208.7M offering dilutes shareholders By Investing.com - Investing.com Australia
Axogen stock falls as $208.7M offering dilutes shareholders - investing.com
Why is Axogen stock sliding today? By Investing.com - Investing.com South Africa
Axogen stock falls as $208.7M offering dilutes shareholders - Investing.com
Axogen Prices $208.7 Million Stock Offering to Fund BioCircuit Acquisition - citybiz
Axogen to Acquire BioCircuit Technologies in $200 Million Nerve Repair Deal - citybiz
Why is Axogen stock sliding today? By Investing.com - Investing.com Canada
Why is Axogen stock sliding today? - investing.com
Axogen acquires BioCircuit Technologies for $200 million - grafa.com
Axogen Announces Pricing Of $208.7 Million Public Offering Of Common Stock - TradingView
AxoGen to Acquire BioCircuit, Expanding Nerve Repair Portfolio - TipRanks
Axogen prices $208.7 million stock offering at $42.50 per share - investing.com
AXGN Looks 171.8% Overvalued on GF Value™ - GuruFocus
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com India
Form 8K Axogen Inc For: 10 September By Investing.com - Investing.com Canada
Form 8K Axogen Inc For: 10 September By Investing.com - Investing.com India
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - manilatimes.net
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com Canada
Axogen Prices $208.7 Million Public Offering of Common Stock to Help Fund BioCircuit Acquisition - Quiver Quantitative
AXGN: Acquisition of a pioneering sutureless nerve repair device is expected to drive growth and innovation - TradingView
Axogen to acquire BioCircuit for $200M, adds nerve repair device - Investing.com UK
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies - GlobeNewswire
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com South Africa
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - globenewswire.com
Nerve repair without stitches is at the center of Axogen’s $200 million deal - Stock Titan
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - Yahoo Finance
Axogen to Acquire BioCircuit Technologies for $200 Million - Yahoo Finance
The first FDA-cleared device to repair cut nerves without stitches is now part of Axogen. - Stock Titan
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - The Manila Times
Axogen, Inc. agreed to acquire BioCircuit Technologies, Inc. for approximately $200 million. - marketscreener.com
Understanding the Setup: (AXGN) and Scalable Risk - Stock Traders Daily
Axogen Director Tyndall Joseph A. Disposes of 3,500 Shares at $49.70 Each - Kalkine Media
Axogen (AXGN) Director Joseph Tyndall Sells 3,500 Shares - GuruFocus
Axogen Inc Stock (AXGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axogen Inc Stock (AXGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| JOSEPH A TYNDALL | Director |
Sep 02 '26 |
Proposed Sale |
49.88 |
3,500 |
174,580 |
0 |
| Wendell Amy McBride | Director |
Aug 11 '26 |
Option Exercise |
14.85 |
13,353 |
198,292 |
121,329 |
| Wendell Amy McBride | Director |
Aug 11 '26 |
Sale |
48.42 |
13,353 |
646,592 |
107,976 |
| AMY MCBRIDE-WENDELL | Director |
Aug 11 '26 |
Proposed Sale |
48.22 |
13,353 |
643,882 |
0 |
| Began Marc A | EVP & General Counsel |
Aug 10 '26 |
Sale |
47.34 |
67,500 |
3,195,788 |
50,135 |
| MARC BEGAN | Officer |
Aug 10 '26 |
Proposed Sale |
46.43 |
67,500 |
3,134,025 |
0 |
| Began Marc A | EVP & General Counsel |
Aug 10 '26 |
Option Exercise |
8.16 |
67,500 |
550,800 |
117,635 |
| KATHY WEILER | Director |
Aug 07 '26 |
Proposed Sale |
44.35 |
14,150 |
627,552 |
0 |
| Weiler Kathy Johnson | Director |
Aug 07 '26 |
Sale |
45.30 |
14,150 |
640,967 |
0 |
| Wendell Amy McBride | Director |
Jun 19 '26 |
Option Exercise |
0.00 |
14,150 |
0 |
107,976 |
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):